ScholarIQanswers from OpenAlex & ORCID
V. Gounant
ResearcherPublications, citations & collaboration network
V. Gounant is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does V. Gounant have?
ScholarIQindexed works
V. Gounant has 321 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does V. Gounant have?
ScholarIQcitation count
V. Gounant has 6,106 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of V. Gounant?
ScholarIQh-index
V. Gounant has an h-index of 35 in OpenAlex.
What is the i10-index of V. Gounant?
ScholarIQi10-index
V. Gounant has an i10-index of 79 in OpenAlex.
What is the ORCID of V. Gounant?
ScholarIQorcid
The ORCID for V. Gounant is on the source record.
What is the OpenAlex record for V. Gounant?
ScholarIQopenalex
The OpenAlex for V. Gounant is on the source record.
What are the most-cited papers on V. Gounant?
ScholarIQmost cited works
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, R. Corre, I. Monnet, V. Gounant, F. Rivière, Henri Janicot, Radj Gervais, Chrystèle Locher, B. Milleron, Quan Le Tran, Marie-Paule Lebitasy, Franck Morin, Christian Créveuil, Jean‐Jacques Parienti, Arnaud Scherpereel
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Lionel Uwer, J. Hureaux, Florian Guisier, D. Carmier, J. Madelaine, Josiane Otto, V. Gounant, P. Merle, Pierre Mourlanette, Olivier Molinier, Aldo Renault, Audrey Rabeau, Martine Antoine, Marc G. Denis, Sébastien Bommart, Alexandra Langlais, Franck Morin, Pierre-Jean Souquet
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Sandra Assoun, Nathalie Théou–Anton, Marina Nguenang, Aurélie Cazes, Claire Danel, Baptiste Abbar, Johan Pluvy, V. Gounant, Antoine Khalil, Céline Namour, Solenn Brosseau, Gérard Zalcman